366 related articles for article (PubMed ID: 30563158)
1. Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy.
Kasprzak A; Adamek A
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30563158
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium.
Benetti A; Berenzi A; Gambarotti M; Garrafa E; Gelati M; Dessy E; Portolani N; Piardi T; Giulini SM; Caruso A; Invernici G; Parati EA; Nicosia R; Alessandri G
Cancer Res; 2008 Oct; 68(20):8626-34. PubMed ID: 18922939
[TBL] [Abstract][Full Text] [Related]
3. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma.
Yang LY; Lu WQ; Huang GW; Wang W
BMC Cancer; 2006 May; 6():110. PubMed ID: 16650286
[TBL] [Abstract][Full Text] [Related]
4. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF.
Yao Y; Pan Y; Chen J; Sun X; Qiu Y; Ding Y
Ann Clin Lab Sci; 2007; 37(1):39-48. PubMed ID: 17311868
[TBL] [Abstract][Full Text] [Related]
5. Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma.
Yu D; Zhuang L; Sun X; Chen J; Yao Y; Meng K; Ding Y
BMC Cancer; 2007 Jul; 7():122. PubMed ID: 17608955
[TBL] [Abstract][Full Text] [Related]
6. The Role of Endoglin in Hepatocellular Carcinoma.
Jeng KS; Sheen IS; Lin SS; Leu CM; Chang CF
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809908
[TBL] [Abstract][Full Text] [Related]
7. Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma.
Zheng N; Zhang S; Wu W; Zhang N; Wang J
Pharmacol Res; 2021 Apr; 166():105507. PubMed ID: 33610718
[TBL] [Abstract][Full Text] [Related]
8. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Xiong YQ; Sun HC; Zhang W; Zhu XD; Zhuang PY; Zhang JB; Wang L; Wu WZ; Qin LX; Tang ZY
Clin Cancer Res; 2009 Aug; 15(15):4838-46. PubMed ID: 19638466
[TBL] [Abstract][Full Text] [Related]
9. Microvascular density of regenerative nodule to small hepatocellular carcinoma by automated analysis using CD105 and CD34 immunoexpression.
Paschoal JP; Bernardo V; Canedo NH; Ribeiro OD; Caroli-Bottino A; Pannain VL
BMC Cancer; 2014 Feb; 14():72. PubMed ID: 24507660
[TBL] [Abstract][Full Text] [Related]
10. Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.
Tanaka S; Arii S
Int J Clin Oncol; 2006 Apr; 11(2):82-9. PubMed ID: 16622743
[TBL] [Abstract][Full Text] [Related]
11. The Role of Angiogenesis in Hepatocellular Carcinoma.
Morse MA; Sun W; Kim R; He AR; Abada PB; Mynderse M; Finn RS
Clin Cancer Res; 2019 Feb; 25(3):912-920. PubMed ID: 30274981
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.
Yao C; Wu S; Kong J; Sun Y; Bai Y; Zhu R; Li Z; Sun W; Zheng L
Cancer Biol Med; 2023 Jan; 20(1):25-43. PubMed ID: 36647777
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of TGF-β/SMAD3/NF-κB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells.
Jiang F; Wang X; Liu Q; Shen J; Li Z; Li Y; Zhang J
Toxicol Lett; 2014 Nov; 231(1):55-61. PubMed ID: 25196641
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features.
Ribeiro OD; Canedo NH; Pannain VL
Clinics (Sao Paulo); 2016 Nov; 71(11):639-643. PubMed ID: 27982164
[TBL] [Abstract][Full Text] [Related]
15. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
Salvesen HB; Gulluoglu MG; Stefansson I; Akslen LA
APMIS; 2003 Nov; 111(11):1011-8. PubMed ID: 14629267
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta1 induces microvascular abnormalities through a down-modulation of neural cell adhesion molecule in human hepatocellular carcinoma.
Balzarini P; Benetti A; Invernici G; Cristini S; Zicari S; Caruso A; Gatta LB; Berenzi A; Imberti L; Zanotti C; Portolani N; Giulini SM; Ferrari M; Ciusani E; Navone SE; Canazza A; Parati EA; Alessandri G
Lab Invest; 2012 Sep; 92(9):1297-309. PubMed ID: 22732936
[TBL] [Abstract][Full Text] [Related]
17. [Tumor microvascular density detected by anti-CD105 and anti-CD34 in hepatocellular carcinoma patients and its predictive value of tumor recurrence after liver transplantation].
Wang Y; Zhang XH; Guo P; Yan LN; He D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):818-21. PubMed ID: 21302449
[TBL] [Abstract][Full Text] [Related]
18. Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa.
Bellone G; Gramigni C; Vizio B; Mauri FA; Prati A; Solerio D; Dughera L; Ruffini E; Gasparri G; Camandona M
Int J Oncol; 2010 Nov; 37(5):1153-65. PubMed ID: 20878063
[TBL] [Abstract][Full Text] [Related]
19. Vascular changes in hepatocellular carcinoma.
Yang ZF; Poon RT
Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver.
Ho JW; Poon RT; Sun CK; Xue WC; Fan ST
World J Gastroenterol; 2005 Jan; 11(2):176-81. PubMed ID: 15633211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
